• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

    6/5/25 1:58:00 PM ET
    $AMGN
    $DIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Get the next $AMGN alert in real time by email

    TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

    The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Disney's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?studyid=16958122.

    A full report on Disney will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc.  (AMGN: NASDAQ), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-the-walt-disney-co-nyse-dis-302474596.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMGN
    $DIS

    CompanyDatePrice TargetRatingAnalyst
    Walt Disney Company
    $DIS
    6/3/2025$135.00 → $140.00Buy
    Rosenblatt
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Walt Disney Company
    $DIS
    4/21/2025$112.00Peer Perform → Outperform
    Wolfe Research
    Walt Disney Company
    $DIS
    1/22/2025$125.00Buy
    Citigroup
    Walt Disney Company
    $DIS
    1/7/2025$100.00 → $147.00Neutral → Buy
    Redburn Atlantic
    Amgen Inc.
    $AMGN
    12/10/2024$256.00Underperform
    BofA Securities
    Walt Disney Company
    $DIS
    12/5/2024$120.00Hold
    Jefferies
    More analyst ratings

    $AMGN
    $DIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      2/13/24 4:58:51 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Walt Disney Company (Amendment)

      SC 13G/A - Walt Disney Co (0001744489) (Subject)

      2/13/24 4:55:53 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      1/30/24 11:35:57 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

      THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found

      6/5/25 4:01:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

      TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August. The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for inv

      6/5/25 1:58:00 PM ET
      $AMGN
      $DIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

      Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy  Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3

      6/2/25 8:04:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    SEC Filings

    See more
    • SEC Form 11-K filed by Walt Disney Company

      11-K - Walt Disney Co (0001744489) (Filer)

      6/2/25 4:31:05 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • SEC Form 11-K filed by Walt Disney Company

      11-K - Walt Disney Co (0001744489) (Filer)

      6/2/25 4:30:38 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • SEC Form SD filed by Walt Disney Company

      SD - Walt Disney Co (0001744489) (Filer)

      5/22/25 4:50:32 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcdonald Calvin bought $999,994 worth of Disney Common Stock (11,756 units at $85.06), increasing direct ownership by 111% to 22,313 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      8/9/24 4:33:36 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Gorman James P bought $2,120,628 worth of Disney Common Stock (20,000 units at $106.03), increasing direct ownership by 4,283% to 20,467 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      5/9/24 7:06:37 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Chang Amy bought $99,918 worth of Disney Common Stock (1,078 units at $92.69), increasing direct ownership by 21% to 6,216 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      12/8/23 4:59:03 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    Leadership Updates

    Live Leadership Updates

    See more
    • The Walt Disney Company Launches Inaugural, Company-Wide "Disney Week of Wishes" Campaign to Celebrate World Wish Day With Make-A-Wish

      As the world's largest wish granter for Make-A-Wish, Disney grants a wish every hour of every day all year long Today, The Walt Disney Company (NYSE:DIS) kicks off a weeklong company-wide campaign to celebrate its 45-year relationship with Make-A-Wish® by launching the first ever "Disney Week of Wishes." During this unprecedented week, Disney is honoring World Wish Day on April 29 by sharing unique wishes selected by Make-A-Wish kids that only Disney can make come true. This includes a wish-granting moment on American Idol, a Princess-themed ball for nearly 50 families at Disney World, and making one girl's wish of meeting a star of the Marvel Cinematic Universe come true. The unique power

      4/28/25 10:00:00 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • AI and Quantum Computing Could Reshape the S&P 500--What Investors Need to Know

      USA News Group News Commentary Issued on behalf of Scope Technologies Corp. VANCOUVER, BC , Jan. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – The market is witnessing another tech revolution so far in 2025, kicking off the Trump presidency with the massive $500-billion Stargate AI project, which sent the S&P 500 to a new high. In the past two weeks, the tech industry has witnessed significant advancements in both artificial intelligence (AI) and quantum computing, signaling a transformative era for various sectors. Notably, quantum computing stocks have captured investors' attention, competing with AI stocks. Despite a recent roller coaster in the stocks of quantum computing com

      1/31/25 9:49:00 AM ET
      $DIS
      $EA
      $META
      $MSFT
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      Computer Software: Prepackaged Software
      Technology

    $AMGN
    $DIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Business Development Khosla Rachna sold $434,520 worth of shares (1,500 units at $289.68), decreasing direct ownership by 16% to 8,162 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      6/6/25 7:49:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miles Amy E was granted 809 shares, increasing direct ownership by 20% to 4,842 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:07:13 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kullman Ellen Jamison was granted 809 shares, increasing direct ownership by 6% to 13,467 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:06:19 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Financials

    Live finance-specific insights

    See more
    • IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

      Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy  Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3

      6/2/25 8:04:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • The Walt Disney Company Reports Second Quarter and Six Months Earnings for Fiscal 2025

      The Walt Disney Company (NYSE:DIS) today reported earnings for its second fiscal quarter ended March 29, 2025. Financial Results for the Quarter: Revenues increased 7% for Q2 to $23.6 billion from $22.1 billion in Q2 fiscal 2024 Income before income taxes increased $2.4 billion for Q2 to $3.1 billion from $0.7 billion in Q2 fiscal 2024 Total segment operating income(1) increased 15% for Q2 to $4.4 billion from $3.8 billion in Q2 fiscal 2024 Diluted earnings per share (EPS) for Q2 improved to $1.81 from a loss per share of $0.01 in Q2 fiscal 2024, and adjusted EPS(1) increased 20% for Q2 to $1.45 from $1.21 in Q2 fiscal 2024   (1)   Total segment operating income and dil

      5/7/25 6:50:00 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered

      5/1/25 4:01:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rosenblatt reiterated coverage on Walt Disney with a new price target

      Rosenblatt reiterated coverage of Walt Disney with a rating of Buy and set a new price target of $140.00 from $135.00 previously

      6/3/25 9:00:58 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Guggenheim resumed coverage on Amgen with a new price target

      Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

      5/20/25 8:11:08 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Amgen with a new price target

      Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

      4/22/25 7:29:10 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care